Prevention and Treatment of Type 1 Diabetes with Insulin Analog Molecules

Diamune specializes in the development and production of innovative IgG Fc-Fusion insulin analogs. Meticulously engineered to mitigate and prevent autoimmune diabetes via immune modulation, Diamune also houses a “once-a-week” Ultra Long-Acting Insulin to elevate standards of diabetes management.

This is a subhead – Heading 3

AKS-107 and AKS-440 blandit iaculis ornare. Duis faucibus mauris pellentesque elementum rhoncus. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos:

  • These are sample bullets copied from the Vakston website
  • Reduced development time and cost
  • No cold chain restrictions – shelf stable for > 6 months
  • Versatile and customizable – enables pipeline expansion in therapeutic vaccines
  • First-in-class tolerance and efficacy
  • Self-adjuvanted
  • Best-in-class booster across new variants, long-lasting durable neutralizing immune response

 

Current pipeline indications in development or under consideration include: lorem ipsum, solor divit, e pluribus unum.

Diamune Pipeline

candidate
indication
mechanism
partner
Discovery
Pre-Clinical
Phase 1
Phase II
Phase III
Market
AKS-107
T1D Prevention/Intervention
Inactive insulin antigen Fc analog to interrupt insulin-specific autoimmunity
Indication: T1D Prevention/Intervention
Pre-Clinical

AKS-107 is an Fc-insulin fusion protein designed to interrupt the process leading to insulin autoimmunity. Diamune Therapeutics, Inc. has licensed this patent from Akston Biosciences Corporation to continue the development that was begun with a partnership with the Helmsley Charitable Trust and the National Institutes of Health (NIH) in the early development stages.

Patent Info
AKS-440
Once-a-Week Insulin T1D (+ T2D)
Ultra long-acting insulin Fc analog
Indication: Once-a-Week Insulin T1D (+ T2D)
Pre-Clinical

AKS-440 is a novel human insulin candidate based on an Fc-fusion protein platform, intended to be a once-a-week injectable diabetes therapy. Diamune Therapeutics, Inc. has licensed this patent from Akston Biosciences Corporation to continue the development of this therapy. It is currently in pre-clinical development.

Patent Info

Ambifect Vaccine Fc-fusion Analogs

This paragraph will introduce the two candidates that will be shown in the updated video – AKS-107: Human Type 1 Diabetes and AKS-440: Human Weekly Insulin.

 

 

Product Information

This is a subhead – Heading 3

AKS-107 and AKS-440 blandit iaculis ornare. Duis faucibus mauris pellentesque elementum rhoncus. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos:

Partnering with Diamune:

A Call for Collaboration and Investment

We believe in the power of collaboration to drive scientific breakthroughs and enhance patient outcomes.

At Diamune, we are committed to revolutionizing diabetes care through our innovative Fc-Fusion insulin analogs. As we continue to push the boundaries of what is possible in diabetes management, we seek strategic partnerships and investments to accelerate our mission. We invite investors, research institutions, and healthcare companies to join us in this journey. 

If you share our passion for transforming diabetes management and are interested in learning more about partnership or investment opportunities, please reach out to us at info@diamune.com. Together, we can make a lasting impact on the lives of those affected by diabetes.